{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T13:38:00Z","timestamp":1764596280316,"version":"3.46.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer (BC) is a highly heterogeneous malignancy with limited molecular biomarkers and therapeutic targets. The S100 protein family, a group of calcium-binding proteins, has emerged as a crucial regulator in cancer development. However, their mechanistic roles and clinical significance in BC remain underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review summarizes the current understanding of the expression patterns, biological functions, and signaling mechanisms of key S100 family members in BC, integrating data from transcriptomic studies, public databases (The Cancer Genome Atlas Program, Gene Expression Omnibus), and recent preclinical research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>S100 family members such as S100A8, S100A9, S100A13, and S100A6 are upregulated in advanced BC and are associated with tumor progression, immune suppression, and poor prognosis. In contrast, S100C exhibits tumor-suppressive properties. Mechanistically, S100 proteins promote epithelial-mesenchymal transition, angiogenesis, and immune evasion by activating receptor for advanced glycation end products(RAGE) and toll-like receptor 4 (TLR4)-mediated signaling pathways. Emerging evidence supports the development of S100-targeted therapeutics including small molecules, monoclonal antibodies, and RAGE inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>S100 proteins represent promising biomarkers and therapeutic targets in BC. Integrating S100-based profiling into clinical practice may improve molecular classification, prognostication, and personalized treatment. Future efforts should focus on resolving protein redundancy, validating context-specific functions, and advancing drug development for clinical translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1683039","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T13:23:11Z","timestamp":1764595391000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The S100 protein family in bladder cancer: mechanisms, clinical value, and targeted therapeutic prospects"],"prefix":"10.3389","volume":"15","author":[{"given":"Lihao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lige","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijia","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxin","family":"Ao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiabing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nrc3893","article-title":"S100 proteins in cancer","volume":"15","author":"Bresnick","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3901\/JME.2014.16.089","article-title":"S100 protein family in human cancer","volume":"4","author":"Chen","year":"2014","journal-title":"Am J Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/0143-4160(91)90040-l","article-title":"Perspectives in S-100 protein biology. Review article","volume":"12","author":"Donato","year":"1991","journal-title":"Cell Calcium"},{"key":"B4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/bs.acc.2020.02.006","article-title":"S100 family proteins in inflammation and beyond","volume":"98","author":"Sreejit","year":"2020","journal-title":"Adv Clin Chem"},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s13148-011-0023-9","article-title":"Epigenetic regulation of S100 protein expression","volume":"2","author":"Le\u015bniak","year":"2011","journal-title":"Clin Epigenet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2007.04.009","article-title":"A review of the S100 proteins in cancer","volume":"34","author":"Salama","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2005.10.013","article-title":"S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells","volume":"312","author":"Hermani","year":"2006","journal-title":"Exp Cell Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18016","article-title":"S100A4 in cancer progression and metastasis: A systematic review","volume":"8","author":"Fei","year":"2017","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-011-9338-4","article-title":"S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence","volume":"31","author":"Mishra","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12551-018-0471-y","article-title":"S100 proteins as therapeutic targets","volume":"10","author":"Bresnick","year":"2018","journal-title":"Biophys Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.48.5.269","article-title":"Bladder cancer: state-of-the-art care","volume":"48","author":"Droller","year":"1998","journal-title":"CA Cancer J Clin"},{"key":"B13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","volume":"21","author":"Guo","year":"2024","journal-title":"Nat Rev Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666210309111731","article-title":"Bladder cancer: update on risk factors, molecular and ultrastructural patterns","volume":"28","author":"Mikhaleva","year":"2021","journal-title":"Curr Med Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65644-1","article-title":"Familial transitional cell carcinoma","volume":"156","author":"Kiemeney","year":"1996","journal-title":"J Urol"},{"key":"B16","article-title":"Molecular genetics of bladder cancer: targets for diagnosis and therapy","volume":"25","author":"Baffa","year":"2006","journal-title":"J Exp Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s13040-016-0119-z","article-title":"Complex systems analysis of bladder cancer susceptibility reveals a role for decarboxylase activity in two genome-wide association studies","volume":"9","author":"Cheng","year":"2016","journal-title":"BioData Min"},{"key":"B18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s43141-021-00182-7","article-title":"Implications of targeted next-generation sequencing for bladder cancer: report of four cases","volume":"19","author":"Khalifa","year":"2021","journal-title":"J Genet Eng Biotechnol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.5858\/arpa.2018-0329-RA","article-title":"Bladder cancer in the genomic era","volume":"143","author":"Guo","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M115.051524","article-title":"Comparative tissue proteomics of microdissected specimens reveals novel candidate biomarkers of bladder cancer","volume":"14","author":"Chen","year":"2015","journal-title":"Mol Cell Proteomics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-012-0097-6","article-title":"The PPI network and cluster ONE analysis to explain the mechanism of bladder cancer","volume":"17","author":"Wan","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"10997","DOI":"10.3390\/ijms252010997","article-title":"Molecular landscape of bladder cancer: key genes, transcription factors, and drug interactions","volume":"25","author":"Danishuddin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2013.08.008","article-title":"Biomarkers in bladder cancer: translational and clinical implications","volume":"89","author":"Cheng","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28175","article-title":"Exploiting protein family and protein network data to identify novel drug targets for bladder cancer","volume":"13","author":"Adeyelu","year":"2022","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.606.11.2","article-title":"Down-regulation of S100C is associated with bladder cancer progression and poor survival","volume":"11","author":"Memon","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02097.x","article-title":"Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers","volume":"46","author":"Cross","year":"2005","journal-title":"Histopathology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-261","article-title":"In silico analysis and verification of S100 gene expression in gastric cancer","volume":"8","author":"Liu","year":"2008","journal-title":"BMC Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000162022.36772.a4","article-title":"Use of the novel marker BLCA-1 for the detection of bladder cancer","volume":"174","author":"Myers-Irvin","year":"2005","journal-title":"J Urol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1021\/pr900273u","article-title":"Serum and tissue profiling in bladder cancer combining protein and tissue arrays","volume":"9","author":"Orenes-Pi\u00f1ero","year":"2010","journal-title":"J Proteome Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2011.00008","article-title":"Targeting S100P inhibits colon cancer growth and metastasis by Lentivirus-mediated RNA interference and proteomic analysis","volume":"17","author":"Jiang","year":"2011","journal-title":"Mol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0545","article-title":"The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D","volume":"67","author":"Whiteman","year":"2007","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7999","article-title":"Cancer-associated S100P protein binds and inactivates p53, permits therapy-induced senescence and supports chemoresistance","volume":"7","author":"Gibadulinova","year":"2016","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102489","article-title":"Unraveling the protein post-translational modification landscape: Neuroinflammation and neuronal death after stroke","volume":"101","author":"Tao","year":"2024","journal-title":"Ageing Res Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/156652413804486214","article-title":"Functions of S100 proteins","volume":"13","author":"Donato","year":"2013","journal-title":"Curr Mol Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-241","article-title":"Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-kappaB","volume":"10","author":"Grotter\u00f8d","year":"2010","journal-title":"BMC Cancer"},{"key":"B36","article-title":"Possible mechanism for regulation of inflammatory responses with the S100A8\/A9 protein","volume":"58","author":"Namura","year":"2010","journal-title":"Rinsho Byori"},{"key":"B37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12935-021-01949-1","article-title":"Dual effects of targeting S100A11 on suppressing cellular metastatic properties and sensitizing drug response in gastric cancer","volume":"21","author":"Cui","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/BF00437475","article-title":"Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target","volume":"15","author":"Crew","year":"1996","journal-title":"Cancer Metastasis Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2017.4226","article-title":"S100B expression in breast cancer as a predictive marker for cancer metastasis","volume":"52","author":"Yen","year":"2018","journal-title":"Int J Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1186\/s12885-023-11490-1","article-title":"S100P as a potential biomarker for immunosuppressive microenvironment in pancreatic cancer: a bioinformatics analysis and in vitro study","volume":"23","author":"Hao","year":"2023","journal-title":"BMC Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7024","article-title":"Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence","volume":"7","author":"Parodi","year":"2016","journal-title":"Oncotarget"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1216134","article-title":"Corrigendum: Label-free LC-MS\/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602406","article-title":"The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder","volume":"92","author":"Hilmy","year":"2005","journal-title":"Br J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1537808","article-title":"Redefining bladder cancer treatment: innovations in overcoming drug resistance and immune evasion","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.125898","article-title":"Sumoylation and nuclear translocation of S100A4 regulate IL-1beta-mediated production of matrix metalloproteinase-13","volume":"285","author":"Miranda","year":"2010","journal-title":"J Biol Chem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1164166","article-title":"The role of the ERK signaling pathway in promoting angiogenesis for treating ischemic diseases","volume":"11","author":"Song","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-21","article-title":"Identification of S100A8-correlated genes for prediction of disease progression in non-muscle invasive bladder cancer","volume":"10","author":"Kim","year":"2010","journal-title":"BMC Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"10999","DOI":"10.1038\/s41598-020-67929-z","article-title":"Circulating proteomic signature for detection of biomarkers in bladder cancer patients","volume":"10","author":"Nedjadi","year":"2020","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100472","article-title":"Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight","volume":"2","author":"Hurst","year":"2021","journal-title":"Cell Rep Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7149408","article-title":"S100A9 increases IL-6 and RANKL expressions through MAPKs and STAT3 signaling pathways in osteocyte-like cells","volume":"2020","author":"Takagi","year":"2020","journal-title":"BioMed Res Int"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2009.09.031","article-title":"Silencing of the annexin II gene down-regulates the levels of S100A10, c-Myc, and plasmin and inhibits breast cancer cell proliferation and invasion","volume":"31","author":"Zhang","year":"2010","journal-title":"Saudi Med J"},{"key":"B52","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/biom12040519","article-title":"A structural perspective on calprotectin as a ligand of receptors mediating inflammation and potential drug target","volume":"12","author":"Garcia","year":"2022","journal-title":"Biomolecules"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00418-022-02120-1","article-title":"S100A1 expression characterizes terminally differentiated superficial cells in the urothelium of the murine bladder and ureter","volume":"158","author":"Qasrawi","year":"2022","journal-title":"Histochem Cell Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1186\/s12885-023-11182-w","article-title":"A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer","volume":"23","author":"Cai","year":"2023","journal-title":"BMC Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12885-015-1059-6","article-title":"Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion","volume":"15","author":"Tanaka","year":"2015","journal-title":"BMC Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2940","article-title":"Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study","volume":"13","author":"Dyrskj\u00f8t","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2018.09.007","article-title":"S100 proteins in acute myeloid leukemia","volume":"20","author":"Brenner","year":"2018","journal-title":"Neoplasia"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2021.1937122","article-title":"Discerning the promising binding sites of S100\/calgranulins and their therapeutic potential in atherosclerosis","volume":"31","author":"Singh","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2017.08.147","article-title":"RAGE maintains high levels of NF\u03baB and oncogenic Kras activity in pancreatic cancer","volume":"493","author":"Azizan","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e1072672","DOI":"10.1080\/2162402X.2015.1072672","article-title":"Tasquinimod targets suppressive myeloid cells in the tumor microenvironment","volume":"8","author":"Shen","year":"2019","journal-title":"Oncoimmunology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/s41467-022-29151-5","article-title":"S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110156","article-title":"Roles of S100 family members in drug resistance in tumors: Status and prospects","volume":"127","author":"Hua","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1187741","article-title":"The functions and regulatory pathways of S100A8\/A9 and its receptors in cancers","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Pharmacol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02243","article-title":"S100A9 regulates MDSCs-mediated immune suppression via the RAGE and TLR4 signaling pathways in colorectal carcinoma","volume":"10","author":"Huang","year":"2019","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.bbamcr.2008.11.016","article-title":"Binding of S100 proteins to RAGE: an update","volume":"1793","author":"Leclerc","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2174\/156800907780618329","article-title":"Metastasis-associated protein S100A4: spotlight on its role in cell migration","volume":"7","author":"Tarabykina","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12808","article-title":"Interaction of extracellular S100A4 with RAGE prompts prometastatic activation of A375 melanoma cells","volume":"20","author":"Herwig","year":"2016","journal-title":"J Cell Mol Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01908","article-title":"S100 proteins as an important regulator of macrophage inflammation","volume":"8","author":"Xia","year":"2017","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"9899","DOI":"10.3390\/ijms25189899","article-title":"Protein-based predictive biomarkers to personalize neoadjuvant therapy for bladder cancer-A systematic review of the current status","volume":"25","author":"Bedore","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3109\/10408363.2015.1033610","article-title":"Molecular markers in bladder cancer: Novel research frontiers","volume":"52","author":"Sanguedolce","year":"2015","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28723","article-title":"Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy","volume":"16","author":"Hasan","year":"2025","journal-title":"Oncotarget"},{"key":"B73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/117727190700200018","article-title":"Biomarkers in bladder cancer: present status and perspectives","volume":"2","author":"Kim","year":"2007","journal-title":"biomark Insights"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0913660107","article-title":"Phenothiazines inhibit S100A4 function by inducing protein oligomerization","volume":"107","author":"Malashkevich","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B75","doi-asserted-by":"publisher","first-page":"17730","DOI":"10.1038\/s41598-025-01271-0","article-title":"Identifying RAGE inhibitors as potential therapeutics for Alzheimer\u2019s disease via integrated in-silico approaches","volume":"15","author":"Bhogal","year":"2025","journal-title":"Sci Rep"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0208-0","article-title":"Molecular and histopathology directed therapy for advanced bladder cancer","volume":"16","author":"Alifrangis","year":"2019","journal-title":"Nat Rev Urol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.887686","article-title":"Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow","volume":"9","author":"Su","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2024.2428747","article-title":"Biomarkers of treatment response in bladder cancer","volume":"24","author":"Heard","year":"2024","journal-title":"Expert Rev Mol Diagn"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1683039\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T13:23:12Z","timestamp":1764595392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1683039\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":78,"alternative-id":["10.3389\/fonc.2025.1683039"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1683039","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"article-number":"1683039"}}